{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
icosapent ethyl
to a specific field?
Status:
Investigational
Source:
INN:bifepramide [INN]
Source URL:
Class (Stereo):
CHEMICAL (UNKNOWN)
Bifepramide, (+)- belong to the class of parasympatholytic agents that reduce the activity of the parasympathetic nervous system.
Status:
Investigational
Source:
NCT00562237: Phase 1 Interventional Terminated Healthy Subjects
(2007)
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Status:
Investigational
Source:
NCT03525795: Phase 1 Interventional Completed Advanced Solid Tumors
(2017)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT01705847: Phase 1 Interventional Completed Lymphoid Malignancies
(2012)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Conditions:
GS-9820 (formerly CAL-120) is an oral, small molecule delta selective Phosphatidylinositol 3-kinases (PI3 kinase) inhibitor, a first in class compound, with greater than 200-fold selectivity in cell-based assays for the delta isoform as compared to other class isoforms. GS-9820 is designed to induce cancer cell death and inhibit signaling pathways associated with cancer cell dependence on the tumor microenvironment. GS-9820 is on the phase I of clinical trial, where has to be determined the appropriate dosing regimen of drug in subjects with lymphoid malignancies.
Status:
Investigational
Source:
NCT00942799: Phase 1 Interventional Completed Solid Tumors
(2009)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
Genz-644282 is a non-camptothecin inhibitor of topoisomerase I with potential antineoplastic activity (IC50=1.2 nM). It was in clinical development for the treatment of the solid tumors but later was discontinued.
Status:
Investigational
Source:
NCT03175354: Phase 2 Interventional Completed Atopic Dermatitis
(2017)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
NCT00970229: Phase 1 Interventional Completed Parkinson Disease
(2009)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
NCT01652742: Phase 1 Interventional Completed Healthy
(2012)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT01793441: Phase 2 Interventional Completed Autism Spectrum Disorder
(2013)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
RO-5028442 (RG7713) is a potent and highly selective arginine vasopressin receptor 1A (V1a) antagonist. This compound has been studied for use in autistic spectrum disorder. A phase I study in adult male high-functioning autistic patients has been completed in 2016 and showed that blockade of the V1a receptor may improve social communication in adults with high-functioning ASD. Eye-tracking results showed an increase in biological motion orienting preference. Only mild or moderate adverse events were reported.
Status:
Investigational
Source:
NCT02666963: Phase 1 Interventional Completed Healthy
(2017)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
